Austar Lifesciences Limited AULSF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 54.70M | 53.75M | 61.28M | 60.69M | 45.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.70M | 53.75M | 61.28M | 60.69M | 45.77M |
| Cost of Revenue | 44.55M | 43.77M | 50.41M | 49.92M | 36.15M |
| Gross Profit | 10.15M | 9.97M | 10.87M | 10.77M | 9.62M |
| SG&A Expenses | 8.62M | 8.47M | 7.63M | 7.56M | 7.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.21M | -1.19M | -357.70K | -354.20K | -836.30K |
| Total Operating Expenses | 53.23M | 52.31M | 59.69M | 59.12M | 44.34M |
| Operating Income | 1.47M | 1.44M | 1.58M | 1.57M | 1.43M |
| Income Before Tax | 1.30M | 1.28M | 1.26M | 1.25M | 2.10M |
| Income Tax Expenses | 646.90K | 635.60K | 603.50K | 597.80K | 462.50K |
| Earnings from Continuing Operations | 650.90K | 639.50K | 653.60K | 647.30K | 1.63M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -29.00K | -28.50K | -32.40K | -32.10K | 95.80K |
| Net Income | 621.80K | 611.00K | 621.10K | 615.20K | 1.73M |
| EBIT | 1.47M | 1.44M | 1.58M | 1.57M | 1.43M |
| EBITDA | 2.59M | 2.54M | 2.67M | 2.64M | 2.44M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 512.58M | 512.58M | 512.58M | 512.58M | 512.58M |
| Average Diluted Shares Outstanding | 512.58M | 512.58M | 512.58M | 512.58M | 512.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |